SpectraCell Receives Patent on its LPPTM Cardiovascular Test
SpectraCell Laboratories has been issued a patent on its cardiovascular test, the Lipoprotein Particle Profile™ which has been commercially available since 2006.
- (1888PressRelease) February 08, 2011 - Houston, TX - SpectraCell Laboratories has recently been awarded a patent on their Lipoprotein Particle Profile™ (LPP™) test which is used to measure cardiovascular risk. The LPP™ has been commercially available since 2006, and is a type of advanced cholesterol test that measures lipoprotein subgroups. The LPP™ gives more accurate estimation of cardiovascular risk compared to a routine cholesterol test.
The patent was awarded for use of a "Method for Analyzing Blood for Lipoprotein Components." Specifically, the LPP™ test utilizes a patented analytical ultracentrifugation method for separating lipoprotein subclasses. This separation method for LPP™ originated at Texas A & M University and was further developed by Dr. Jan Troup, the inventor of LPP™ technology, who is also a member of SpectraCell's scientific staff.
"The LPP™ generally doesn't cost the patient any more than a standard cholesterol test, but it gives the doctor much more relevant and accurate information." states Dr. Jan Troup, PhD, and Director of Lipid Science for SpectraCell Laboratories. "Different lipoproteins respond differently to therapy, whether it is statins, fish oils or niacin, for example. The LPP™ enables the doctor to treat appropriately."
In recent years, the medical community has discovered that, beyond "standard" cholesterol tests, an independent factor for heart disease can be determined by measuring the density and number of lipoprotein particles, to which cholesterol is attached. Patients with a normal cholesterol value, but abnormal particle sizes or numbers, can be at serious risk for cardiovascular disease.
In fact, The National Cholesterol Education Program (NCEP) acknowledges that 50% of people that have heart attacks have "normal" cholesterol - that is, cholesterol below 200 mg/dL. NCEP recognizes four risk factors that are not measured with routine cholesterol testing but are all measured by the LPP™ test:
1. RLP - (remnant lipoprotein) more easily converted into arterial plaque than other lipoproteins
2. Lp(a) - a dangerous lipoprotein that contributes to clot formation
3. HDL2b - a type of HDL that indicates how well cholesterol is being cleared from your system
4. Small, dense LDL - easily penetrates vascular wall, causing damage and plaque
The main reason to know NCEP risk factors are that specific lipoproteins respond to specific therapies very differently. The LPP™ is part of the trend toward more individualized medicine. The LPP test, which is done on a fasting blood sample, is usually covered by insurance. Results typically take 3-5 days. For more information, go to www.spectracell.com.
About SpectraCell Laboratories - SpectraCell is a CLIA accredited laboratory that services healthcare providers nationwide by providing advanced clinical testing such as micronutrient testing, telomere analysis, Omega 3 Index and the Lipoprotein Particle Profile™ (LPP™).
SpectraCell's Lipoprotein Particle Profile™ is the most advanced lipoprotein test available. Unlike traditional cholesterol tests, SpectraCell's LPP™ directly measures both the size (density) and number of several classes of lipoprotein particles providing an accurate assessment of cardiovascular risk.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam